Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target
Cancer immunotherapy has made impressive advances in improving the outcome of patients affected by malignant diseases. Nonetheless, some limitations still need to be tackled to more efficiently and safely treat patients, in particular for those affected by solid tumors. One of the limitations is rel...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Frontiers Media S.A.
2024-02-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1356321/full |
| _version_ | 1827351438266728448 |
|---|---|
| author | Marsha Pellegrino Valerio Secli Silvia D’Amico Lucia Lisa Petrilli Matteo Caforio Valentina Folgiero Nicola Tumino Paola Vacca Maria Vinci Doriana Fruci Emmanuel de Billy |
| author_facet | Marsha Pellegrino Valerio Secli Silvia D’Amico Lucia Lisa Petrilli Matteo Caforio Valentina Folgiero Nicola Tumino Paola Vacca Maria Vinci Doriana Fruci Emmanuel de Billy |
| author_sort | Marsha Pellegrino |
| collection | DOAJ |
| description | Cancer immunotherapy has made impressive advances in improving the outcome of patients affected by malignant diseases. Nonetheless, some limitations still need to be tackled to more efficiently and safely treat patients, in particular for those affected by solid tumors. One of the limitations is related to the immunosuppressive tumor microenvironment (TME), which impairs anti-tumor immunity. Efforts to identify targets able to turn the TME into a milieu more auspicious to current immuno-oncotherapy is a real challenge due to the high redundancy of the mechanisms involved. However, the insulin-like growth factor 1 receptor (IGF1R), an attractive drug target for cancer therapy, is emerging as an important immunomodulator and regulator of key immune cell functions. Here, after briefly summarizing the IGF1R signaling pathway in cancer, we review its role in regulating immune cells function and activity, and discuss IGF1R as a promising target to improve anti-cancer immunotherapy. |
| first_indexed | 2024-03-08T02:03:18Z |
| format | Article |
| id | doaj.art-f72a5d87ecd6417d9377f84abca421f8 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T02:03:18Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-f72a5d87ecd6417d9377f84abca421f82024-02-14T04:52:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13563211356321Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising targetMarsha Pellegrino0Valerio Secli1Silvia D’Amico2Lucia Lisa Petrilli3Matteo Caforio4Valentina Folgiero5Nicola Tumino6Paola Vacca7Maria Vinci8Doriana Fruci9Emmanuel de Billy10Oncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyImmunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyImmunology Research Area, Innate Lymphoid Cells Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyOncohematology and Pharmaceutical Factory Research Area, Pediatric Cancer Genetics and Epigenetics Unit, Bambino Gesù Children’s Hospital-IRCCS, Rome, ItalyCancer immunotherapy has made impressive advances in improving the outcome of patients affected by malignant diseases. Nonetheless, some limitations still need to be tackled to more efficiently and safely treat patients, in particular for those affected by solid tumors. One of the limitations is related to the immunosuppressive tumor microenvironment (TME), which impairs anti-tumor immunity. Efforts to identify targets able to turn the TME into a milieu more auspicious to current immuno-oncotherapy is a real challenge due to the high redundancy of the mechanisms involved. However, the insulin-like growth factor 1 receptor (IGF1R), an attractive drug target for cancer therapy, is emerging as an important immunomodulator and regulator of key immune cell functions. Here, after briefly summarizing the IGF1R signaling pathway in cancer, we review its role in regulating immune cells function and activity, and discuss IGF1R as a promising target to improve anti-cancer immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1356321/fullimmuno-oncotherapytumor microenvironmentIGF1Rcancer immunityimmunomodulation |
| spellingShingle | Marsha Pellegrino Valerio Secli Silvia D’Amico Lucia Lisa Petrilli Matteo Caforio Valentina Folgiero Nicola Tumino Paola Vacca Maria Vinci Doriana Fruci Emmanuel de Billy Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target Frontiers in Immunology immuno-oncotherapy tumor microenvironment IGF1R cancer immunity immunomodulation |
| title | Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target |
| title_full | Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target |
| title_fullStr | Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target |
| title_full_unstemmed | Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target |
| title_short | Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target |
| title_sort | manipulating the tumor immune microenvironment to improve cancer immunotherapy igf1r a promising target |
| topic | immuno-oncotherapy tumor microenvironment IGF1R cancer immunity immunomodulation |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1356321/full |
| work_keys_str_mv | AT marshapellegrino manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT valeriosecli manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT silviadamico manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT lucialisapetrilli manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT matteocaforio manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT valentinafolgiero manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT nicolatumino manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT paolavacca manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT mariavinci manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT dorianafruci manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget AT emmanueldebilly manipulatingthetumorimmunemicroenvironmenttoimprovecancerimmunotherapyigf1rapromisingtarget |